Current treatment status-Undergoing active treatment-Minimal response Posts on Medivizor

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

$Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Aug 27, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of daratumumab (D; Darzalex) plus bortezomib (V; Velcade) and dexamethasone (d; Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. Some...

Evaluating the effectiveness and safety of replacing lenalidomide with pomalidomide for the treatment of patients with multiple myeloma who are unresponsive to a lenalidomide-containing combination regimen.

Posted by Medivizor on Feb 5, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of replacing lenalidomide (Revlimid) with pomalidomide (Pomalyst) for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) who were unresponsive to a lenalidomide-containing combination regimen. The data showed that pomalidomide was a safe and effective...

Evaluating the effectiveness of daratumumab-containing regimens in patients with multiple myeloma who are unresponsive to lenalidomide maintenance therapy.

Posted by Medivizor on Sep 11, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-containing regimens in patients with multiple myeloma (MM) unresponsive to lenalidomide (Revlimid) maintenance therapy. The data showed that daratumumab-containing therapies are effective regimens in these patients. Some background Multiple myeloma (MM) is a type...

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Jun 26, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Apr 29, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...

Evaluating CAR-T cell therapies for treating blood cancers

Posted by Medivizor on Oct 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...

Evaluating teclistamab for patients with recurrent or unresponsive multiple myeloma

Posted by Medivizor on Oct 9, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of teclistamab (JNJ-64007957) for patients with recurrent or unresponsive multiple myeloma (MM). This study concluded that this treatment was safe and showed promising effectiveness for these patients. Some background Multiple myeloma is a type of cancer of the bone marrow that can...

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Posted by Medivizor on Aug 22, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that adding isatuximab to the Kd regimen reduced the risk of disease progression or death for these...

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Posted by Medivizor on Jun 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to compare bortezomib (Velcade; V) and carfilzomib (Kyprolis; K) in combination with Cd (cyclophosphamide and dexamethasone) as second line treatment in patients with relapsed multiple myeloma (MM). The authors found the KCd is as effective as VCd and K can also be used as a maintenance treatment in these...

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

$What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?$

Posted by Medivizor on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the treatment schedule for panobinostat (Farydak) tablets combines with subcutaneous (injections under the skin) bortezomib (Velcade) and dexamethasone (Ozurdex) tablets in patients with relapsed/refractory (R/R) multiple myeloma (MM). The study found that 20mg of panobinostat should be given twice...

Does treatment with selinexor, bortezomib and dexamethasone improve the outcome of patients with multiple myeloma?

Posted by Medivizor on Dec 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated if giving patients with aggressive multiple myeloma (MM) a combination of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) could improve their survival. The study suggested that this combination improved patients’ outcomes. Some background Multiple Myeloma (MM) is an...

Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma

$Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma$

Posted by Medivizor on Oct 29, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study compared outcomes of once-weekly (OW) versus twice-weekly (TW) carfilzomib (Kyprolis) plus dexamethasone (Decadron) in Japanese patients with relapsed/refractory (RR) multiple myeloma (MM). The authors found that the OW dosage improved overall response rate (ORR) compared to TW in such patients. Some background RR-MM...

« Older Entries

Current treatment status-Undergoing active treatment-Minimal response Posts on Medivizor

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness and safety of replacing lenalidomide with pomalidomide for the treatment of patients with multiple myeloma who are unresponsive to a lenalidomide-containing combination regimen.

Evaluating the effectiveness of daratumumab-containing regimens in patients with multiple myeloma who are unresponsive to lenalidomide maintenance therapy.

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating CAR-T cell therapies for treating blood cancers

Evaluating teclistamab for patients with recurrent or unresponsive multiple myeloma

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

Does treatment with selinexor, bortezomib and dexamethasone improve the outcome of patients with multiple myeloma?

Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma

Categories

Recent Posts

Archives

Current treatment status-Undergoing active treatment-Minimal response Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email